ReviewClinical pharmacokinetics2021
Clinical Pharmacokinetics of Triazoles in Pediatric Patients.
Review in Clinical pharmacokinetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions.Clinical pharmacokinetics · 2022Pooled it
- Synthesis and biological evaluation of novel β-keto ether-triazole hybrids as dual antimicrobial and anticancer agents.BMC chemistry · 2026Article
- Comparative study of liposomal amphotericin B, posaconazole, and micafungin for primary antifungal prophylaxis in pediatric patients with acute leukemia.Journal of cancer research and clinical oncology · 2025Observational
- TDM-Based Approach for Properly Managing Intravenous Isavuconazole Treatment in a Complex Case Mix of Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2025Article
- Voriconazole in the treatment of pediatric patients with hematologic malignancies and invasive fungal infections: a real-world study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Fluconazole Dosing for the Prevention ofPharmaceutics · 2025Article
- Assessment of the Effective Dose of Isavuconazole, Itraconazole, Posaconazole, and Voriconazole to Achieve Goal Serum Concentrations in Pediatric Patients at a Single Center.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Detection and Management of Invasive Mold Disease in Pediatric Hematological Cancer Patients.Infection and drug resistance · 2025Review
- The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug Monitoring.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT.Microorganisms · 2024Article
- Triazole antifungal drug interactions-practical considerations for excellent prescribing.The Journal of antimicrobial chemotherapy · 2024Review
- Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study.Paediatric drugs · 2024Article
- Influence of Gender, Body Mass Index, and Age on the Pharmacokinetics of Itraconazole in Healthy Subjects: Non-Compartmental Versus Compartmental Analysis.Frontiers in pharmacology · 2022Article
- Necrotizing fasciitis in neonate byAccess microbiology · 2022Article
- Azole Fungicides and Their Endocrine Disrupting Properties: Perspectives on Sex Hormone-Dependent Reproductive Development.Frontiers in toxicology · 2022Review
- A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triazoles represent an important class of antifungal drugs in the prophylaxis and treatment of invasive fungal disease in pediatric patients. Understanding the pharmacokinetics of triazoles in children is crucial to providing optimal care for this vulnerable population. While the pharmacokinetics is extensively studied in adult populations, knowledge on pharmacokinetics of triazoles in children is limited. New data are still emerging despite drugs already going off patent. This review aims to provide readers with the most current knowledge on the pharmacokinetics of the triazoles: fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole. In addition, factors that have to be taken into account to select the optimal dose are summarized and knowledge gaps are identified that require further research. We hope it will provide clinicians guidance to optimally deploy these drugs in the setting of a life-threatening disease in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.